Tuberculosis medical therapy special conditions: Difference between revisions

	Tuberculosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Tuberculosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Children
HIV Coinfection
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Special Conditions
Drug-resistant
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Tuberculosis medical therapy special conditions On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Tuberculosis medical therapy special conditions All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Tuberculosis medical therapy special conditions
CDC on Tuberculosis medical therapy special conditions
Tuberculosis medical therapy special conditions in the news
Blogs on Tuberculosis medical therapy special conditions
Directions to Hospitals Treating Tuberculosis
Risk calculators and risk factors for Tuberculosis medical therapy special conditions

Revision as of 19:09, 17 September 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Depending on the treatment status of the patients, different approaches may be taken:^[1]

After the diagnosis of TB in an HIV-positive patient, not taking antiretroviral therapy (ART), the priority is to initiate treatment for TB, along with co-trimoxazole and ART.
These patients should be treated with the same treatment regimen as non-HIV patients, with the exception that the optional 3 times/week of intensive phase treatment given in non-HIV patients, is mandatory for HIV-positive patients.

@@ Line 8: / Line 8: @@
 Depending on the treatment status of the patients, different approaches may be taken:<ref name="pmid19105873">{{cite journal| author=Harries AD, Zachariah R, Lawn SD| title=Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. | journal=Int J Tuberc Lung Dis | year= 2009 | volume= 13 | issue= 1 | pages= 6-16 | pmid=19105873 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19105873  }} </ref>
 ===Patients Not Taking ART===
-* After the diagnosis of TB in an HIV-positive patient, not taking antiviral therapy, the priority is to initiate treatment for TB, along with co-trimoxazole and ART.
+* After the diagnosis of TB in an HIV-positive patient, not taking [[antiretroviral therapy]] ([[ART]]), the priority is to initiate treatment for TB, along with [[co-trimoxazole]] and [[ART]].
-* These patients should be treated with the same treatment regimen as non-HIV patients, with the exception that the intensive phase given 3 times/week is mandatory in HIV-positive patients.
+* These patients should be treated with the same treatment regimen as non-HIV patients, with the exception that the optional 3 times/week of intensive phase treatment given in non-HIV patients, is mandatory for HIV-positive patients.
 <!--